SPAC Daily: Deep Medicine (DMAQ) Nabs Chinese EV Maker

by | Jul 13, 2022

It’s a continued sign of the times, SPACs are going to find any target that will work. While they certainly aren’t the first to skirt their stated mandate (the mandates are not binding of course), they likely won’t be the last. However, it’s notable when a SPAC is so overtly targeting a specific industry for them to pivot. The latest, Deep Medicine Acquisition Corp. (DMAQ), had of course been targeting healthcare due to the “myriad of the opportunities it offers, as well as our deep expertise in it that can be a source of significant competitive advantage.”

Thus, today, DMAQ announced a $2.55B tie up with Chijet Motor Company, a Chinese automaker that is developing next-gen EV. Little about the deal was made available, and no investor deck that we can see yet. DMAQ isn’t exactly fully up against the gun, they have the option to extend their October deadline twice, albeit at a cost of $0.10 / share each time. Let’s see what happens here.

Not a whole lot to report today aside from extensions and maneuvering. Read below.

Elsewhere in SPACs

  • CHW Acquisition Corp. (CHWA) set its Wag! Labs vote for 7/28. ICYMI we spoke to Wag! CEO Garrett Smallwood on our Podcast recently.
  • Tailwind Acquisition Corp. (TWND) filed a prelim proxy for a 6mo extension, no contribution
  • Foxwayne Enterprises Acquisition Corp. (FOXW) announced that its two 3 month extensions were approved, redemptions not disclosed
  • SCVX Corp. (SCVX) set a date for its second extension of the year, voting for a 9mo extension on 7/27. Just $38M remains in their trust following the last one.
  • 80% of shares redeemed in Lightjump Acquisition Corp. (LJAQ) extension vote

Upcoming SPAC Calendar

Full calendar and SPAC database access here

Recent Analysis

Disclaimer

The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon. 

This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.  

None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by BA that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.  

No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.